Bioinformatics visualisation specialist Qlucore has released the beta version of its Qlucore Omics Explorer 3.3 software, including a completely new Next Generation Sequencing (NGS) Module and range of new functionalities for the base version. The NGS Module will enable additional functionality related to data generated with NGS technologies, making it possible to interactively and dynamically visualise, analyse and explore NGS data.
Qlucore Omics Explorer is a next-generation bioinformatics software program for broad usage known for its friendly user interface and advanced visualisation capabilities that enables biologists and researchers who are not data analysis experts to explore NGS and data, find new answers and generate new hypotheses.
Examples include RNA-seq studies, is one of the most used techniques in modern genetics and cancer research, with the NGS Module enabling a comprehensive and synchronised view of both expression levels and genomic locations. A unique flexibility is handed to the user, who can perform a statistical test in the expression space by simply moving a cut-off slider, observing the result in the Genome browser, one of the main components in the NGS Module which, in combination with the dynamic filters, ensures that the user always visualises the most interesting regions of the genome, minimising the need for zoom and scroll.
For further information on Qlucore and its new software visit www.qlucore.com
Latest from Tom Mulligan
- Gyros Protein Technologies and Fleet Bioprocessing offer assay development and transfer services
- SBRI Healthcare invests £8.7 million in general practice innovation
- SYGNIS AG partners with Abingdon Health in lateral-flow assay design and supply
- Quotient Siences signs cocrystal formulations evaluation agreement with Nuformix
- Optibrium joins eTRANSAFE data standardisation project
- Irvine Scientific increases cell culture dry powder media production capacity
- Horizon Discovery launches genome-wide CRISPR screening services
- Glythera and IONTAS in antibody-drug conjugate licence agreement
- Desktop Genetics opens £1.5 million investment round via SyndicateRoom
- Avacta Group plc establishes US business development team